Abstract: A set of overall 40 carboxamides was prepared from five different natural occurring triterpenoids including oleanolic, ursolic, maslinic, betulinic, and platanic acid. All of which were derived from ethylene diamine holding an additional substituent connected to the ethylene diamine group. These derivatives were evaluated regarding their inhibitory activity of the enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) employing Ellman's assay. We further determined the type of inhibition and inhibition constants. Carboxamides derived from platanic acid have been shown to be potent and selective BChE inhibitors. Especially the mixed-type inhibitor (3β)-N-(2-pyrrolidin-1-ylethyl)-3-acetyloxy-20-oxo-30-norlupan-28-amide (35) showed a remarkably low K i of 0.07 ± 0.01 µM (K i = 2.38 ± 0.48 µM) for the inhibition of BChE.
Introduction
It is now more than a century since Alois Alzheimer, a German physician, described a new disease of the brain [1] , being today one of the most threatening plagues for the elderly and one of the greatest challenges for chemists and biologists. The eponymous disease is today one of the greatest scourges of humanity. Alzheimer's disease (AD), the most common cause of dementia, is a neurodegenerative disorder, causing the progressive loss of cognitive functions and memory. As a result of demographic changes, the number of AD patients is steadily rising. This disease is characterized by an increasing decline in acetylcholine (ACh, neurotransmitter) levels in the cholinergic system [2] . A common strategy for the management of AD is to develop inhibitors that suppress the degradation of ACh caused by hydrolases acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase (BChE, EC 3.1.1.8) .
Ursolic acid (UA), oleanolic acid (OA), maslinic acid (MA), betulinic acid (BA), and platanic acid (PA) are naturally occurring pentacyclic triterpenoids (Figure 1 ), which are widely distributed in various plants. Triterpenes and their derivatives represent a group of pharmacologically interesting substances showing a variety of biological activities such as antitumor [3] , antiviral, and anti-HIV [4, 5] , antibacterial [6, 7] , and antifungal [8] properties. Pentacyclic triterpenoic acids have already been tested for cholinergic activities with moderate anti-cholinesterase activity [9, 10] . Cyclic terpene derivatives, which act as inhibitors of cholinesterases, have been our research focus for a long time. Results from our group have demonstrated that structural modifications of the terpenoid backbone have a high impact onto the inhibitory potential for cholinesterases (ChEs) [11] [12] [13] . Exceptionally good ChE In patients, BChE activity increases with progression of AD while the level of AChE remains constant [16] . Therefore, selective BChE inhibitors represent legitimate therapeutic options to improve the deficit in the neurotransmitter ACh. Deduced from the results of our previous studies, UA, OA, MA, BA and PA carboxamides holding a terminal amino moiety were synthesized from the parent pentacyclic triterpenoic acids. Altogether, 40 different compounds were synthesized and screened for their ChE inhibitory activity using Ellman's assay.
Results and Discussion

Chemistry
Acetylation of triterpenoic acids ( Figure 1 good ChE inhibition has been found for some amino derivatives of platanic acid [12] , as well as for amides of dehydroabietylamine [14] and 12-hydroxydehydroabietylamine [15] . In patients, BChE activity increases with progression of AD while the level of AChE remains constant [16] . Therefore, selective BChE inhibitors represent legitimate therapeutic options to improve the deficit in the neurotransmitter ACh. Deduced from the results of our previous studies, UA, OA, MA, BA and PA carboxamides holding a terminal amino moiety were synthesized from the parent pentacyclic triterpenoic acids. Altogether, 40 different compounds were synthesized and screened for their ChE inhibitory activity using Ellman's assay.
Results and Discussion
Chemistry
Acetylation of triterpenoic acids ( Figure 1 
Biology
In this study, carboxamides with different triterpenoic backbones (ursolic, oleanolic, maslinic, betulinic, and platanic acids), and various amine residues (Scheme 1), were investigated. All compounds 11-50 (except those being not soluble under the conditions of the assay) were subjected to Ellman's assays to determine their inhibition rates and constants (K i for competitive inhibition and K i for uncompetitive inhibition) for the cholinesterases AChE and BChE. Galantamine hydrobromide (GH), one of the gold standard drugs for treating AD symptoms, was used for comparison. In general, pre-screening the 37 triterpenoic acid amides using AChE (electric eel) and BChE (equine serum) identified seventeen compounds as potential inhibitors with inhibition rates equal or even better than GH. The results are summarized in Figures 2 and 3 (details are found in the Supplementary Part,  Table S1 ).
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Figure 2.
Percentage of inhibition of selected carboxamides and galantamine hydrobromide (GH as standard), final concentration of the inhibitor 10 µM, determined by Ellman's assay using acetylcholinesterase (green in the front) and butyrylcholinesterase (purple in the back). Percentage of inhibition of selected carboxamides and galantamine hydrobromide (GH as standard), final concentration of the inhibitor 30 µM, determined by Ellman's assay using acetylcholinesterase (green in the front) and butyrylcholinesterase (purple in the back).
The carboxamides showed a considerably higher inhibition for BChE than for AChE. With the exception of 17 (88.61 ± 0.22%) and 49 (82.72 ± 0.09%), none of the tested compounds showed any notable activity for AChE. Further kinetic studies (see supplementary part, Table 2 ) showed (3β)-N-(2-piperidin-1-ylethyl)- 3-hydroxy-lup-20(29)-en-28-amide (49) as a good mixed-type AChE inhibitor with inhibition constants: Ki = 1.00 ± 0.09 µM and Ki' = 1.42 ± 0.08 µM. The results of the screening experiments suggest that many of the synthesized carboxylic acid amides inhibit BChE activity to a high degree. Fifteen derivatives showed promising inhibitory rates, five of which seemed to inhibit BChE almost completely (88. .60% inhibition rate). The evaluation of the Dixon [17] , CornishBowden [18] , and plots showed that all active compounds were mixed-type Table 1 ). The carboxamides showed a considerably higher inhibition for BChE than for AChE. With the exception of 17 (88.61 ± 0.22%) and 49 (82.72 ± 0.09%), none of the tested compounds showed any notable activity for AChE. Further kinetic studies (see supplementary part, Table 2 ) showed (3β)-N-(2-piperidin-1-ylethyl)- 3-hydroxy-lup-20(29)-en-28-amide (49) as a good mixed-type AChE inhibitor with inhibition constants: Ki = 1.00 ± 0.09 µM and Ki' = 1.42 ± 0.08 µM. The results of the screening experiments suggest that many of the synthesized carboxylic acid amides inhibit BChE activity to a high degree. Fifteen derivatives showed promising inhibitory rates, five of which seemed to inhibit BChE almost completely (88. .60% inhibition rate). The evaluation of the Dixon [17] , CornishBowden [18] , and plots showed that all active compounds were mixed-type The carboxamides showed a considerably higher inhibition for BChE than for AChE. With the exception of 17 (88.61 ± 0.22%) and 49 (82.72 ± 0.09%), none of the tested compounds showed any notable activity for AChE. Further kinetic studies (see Supplementary Part, Table S2 ) showed (3β)-N-(2-piperidin-1-ylethyl)- 3-hydroxy-lup-20(29)-en-28-amide (49) as a good mixed-type AChE inhibitor with inhibition constants: K i = 1.00 ± 0.09 µM and K i = 1.42 ± 0.08 µM. The results of the screening experiments suggest that many of the synthesized carboxylic acid amides inhibit BChE activity to a high degree. Fifteen derivatives showed promising inhibitory rates, five of which seemed to inhibit BChE almost completely (88. .60% inhibition rate). The evaluation of the Dixon [17] , , and plots showed that all active compounds were mixed-type inhibitors with a dominating competitive part. The results from these measurements are compiled in Tables 1 and 2 . Table 1 . Significant results of the BChE inhibition assay. Inhibitory constants (K i and K i in µM), determined using Ellman's assays employing butyrylcholinesterase (BChE, equine serum) with galantamine hydrobromide (GH) as standard. Table 2 . Results of the BChE inhibition assay for platanic acid derivatives. Inhibitory constants (K i and K i in µM), determined using Ellman's assay employing butyrylcholinesterase (BChE, equine serum) with galantamine hydrobromide (GH, K i = 2.30 ± 0.17) as standard. The first set of compounds holding an aminoethyl residue, 11-14 and 16-19, were moderate inhibitors of BChE, with oleanolic acid derivative 17 as the only noteworthy compound of this series (Ki = 1.93 ± 0.13 µM and K i = 7.68 ± 0.61 µM). The next set consisting of triterpenoic amides with a dimethylaminoethyl substituent (21-24 and 26-29) showed good inhibition with K i values between 1.1 and 6.5 µM, respectively. For 2-piperidin-1-ylethyl substituted derivatives (41-44 and 46-49) inhibition constants in the same range were obtained. The group of 2-pyrrolidin-1-ylethyl substituted compounds (31-34 and 36-39) delivered the best results: derivatives 34 (from betulinic acid), 36 (ursolic acid backbone) and 37 (from oleanolic acid), held excellent K i values of 0.39 ± 0.04 µM, 0.47 ± 0.08 µM, and 0.55 ± 0.02 µM, respectively. Compounds showing the highest selectivity (F, expressed by percent inhibition for AChE divided by percent inhibition for BChE) towards BChE were compounds 27 (F = 0.08) and 32 (F = 0.11).
Because of the known inhibitory effect [12] , a set of eight platanic acid derivatives was investigated (Table 2) . Compounds with an aminoethyl residue (15 and 20) were the weakest BChE inhibitors in our test. Compared to the standard GH (K i = 2.30 ± 0.17 µM), 2-(dimethylamino)ethyl substituted derivatives showed good inhibition constants (K i = 1.60 ± 0.13 µM for 25 and K i = 1.12 ± 0.01 µM for 30).
Compounds, carrying a piperidinyl group, showed inhibition even in nanomolar concentrations. For compound 45 (K i = 0.71 ± 0.04 µM) and 50 (K i = 0.97 ± 0.04 µM) excellent values were observed. As already described above, introducing a pyrrolidinyl moiety resulted in compounds with excellent K i values. A very low inhibition constant (K i = 0.45 ± 0.01 µM) was measured for compound 40. The most active compound was (3β)-N-(2-pyrrolidin-1-ylethyl)- 3-acetyloxy-20-oxo-30-norlupan-28-amide (35) showing inhibition constants of K i = 0.07 ± 0.01 µM and K i = 2.38 ± 0.48 µM for BChE. This compound proved to be a selective (F ≈ 0.21) inhibitor for BChE. Except for 15 and 20, all PA-derived compounds showed reasonably high BChE selectivity.
To explain the results from the biological testing, some molecular modeling studies were performed. Table 3 summarizes the results for the most favored docking position of each ligand. From these results, nice correlations between the gold fitness values (the higher the value the better the predicted affinity between ligand enzyme), as well as the interaction energies, with the experimental K i values were established. Figure 4 displays details of the docking arrangements of ligands with BChE. All ligands fit into the binding pocket-preferentially based on hydrophobic interactions ( Figure 5 ) with the side chains of residues W79, W228, L283, Y329, and F326. The highest affinity was observed for 35 ( Figure 4a ). Thus a hydrogen bond of the acetyl group of 35 with the phenolic hydroxyl group of Y79 stabilizes the interaction with BChE. This hydrogen bond, however, is not present in compounds 31 and 34. The modifications in ring E of 31 (six-membered ring) compared to compounds 34 and 35 (five-membered rings) slightly changed the docking arrangement (cf. Figure 4d ) and caused reduced hydrophobic interactions in particular with W79. 
Materials and Methods
General
All chemicals, reagents and technical equipment were purchased in Germany unless otherwise stated. NMR spectra were recorded using the Varian spectrometers Gemini 2000 or Unity 500 (δ given in ppm, J in Hz; typical experiments: H-H-COSY, HMBC, HSQC, NOESY), MS spectra were taken on a Finnigan MAT LCQ 7000 (electrospray, voltage 4.1 kV, sheath gas nitrogen) instrument. The optical rotations were measured on a Perkin-Elmer polarimeter at 20 • C; TLC was performed on silica gel (Merck 5554, detection with cerium molybdate reagent) melting points were uncorrected (Leica hot stage microscope or BÜCHI Melting Point M-565) and elemental analyses were performed on a Foss-Heraeus Vario EL (CHNS) unit. IR spectra were recorded on a Perkin Elmer FT-IR spectrometer Spectrum 1000 or on a Perkin-Elmer Spectrum Two (UATR Two Unit). The solvents were dried according to usual procedures. The purity of the compounds was determined by HPLC and found to be >96%. Ursolic (1), betulinic (4), and platanic acid (5) were obtained from Betulinines (Stříbrná Skalice, Czech Republic), oleanolic acid (2) was purchased from Carbone Scientific (London, UK) and maslinic acid (3) was synthesized as previously described [20, 21] .
Biology
A TECAN SpectraFluorPlus working in the kinetic mode and measuring the absorbance at λ = 415 nm was used for the enzymatic studies. Acetylcholinesterase (from Electrophorus electricus), 5,5 -dithiobis-(2-nitrobenzoic acid) (DTNB) and acetylthiocholine iodide were purchased from Sigma. Butyrylcholinesterase (from equine serum) was purchased from Fluka. Preparation of the solutions, assay procedure, as well as molecular modeling conditions can be found in the Supplementary Materials.
Experimental
General
The preparation of the platanic carboxamides 15, 20, 25, 30, 35, and 40 was performed as previously described [12, 22] . Betulinic and ursolic carboxamides 11, 14, 16, 19, 21, 24, 26, 29, 31 , 34, 36, 39, 41, 44, 46, and 49 were prepared as previously reported in the literature [23] . Experimental procedures and full analytical data of these compounds can be found in the Supplementary Materials.
General Procedure A for the Acetylation of Triterpenoic Acids (6-10)
To a solution of triterpenoic acid 1-5 (11 mmol) in dry DCM (150 mL) was added triethylamine (4.6 mL, 33 mmol), acetic anhydride (3.1 mL, 33 mmol) and DMAP (cat.). After stirring for two days at 25 • C, a saturated solution of NH 3 in MeOH was added (3 mL) and the mixture was stirred for another 30 min. Dilution with DCM and subsequent aqueous work-up provided crude acetates. Recrystallization from EtOH yielded acetates 6-10 (90-96%) as colorless solids, whose spectroscopic data were in full agreement with data from the literature.
General Procedure B for the Synthesis of Triterpenoic Amides (11-15, 21-25, 31-35, and 41-45)
Triterpenoic acetates 6-10 (0.8 mmol) were each dissolved in dry DCM (15 mL), cooled to 0 • C, then oxalyl chloride (3.2 mmol) and dry DMF (3 drops) were added. After warming to 25 • C, the mixture was stirred for 1 h. The solvent was removed under reduced pressure, re-evaporated with dry THF (4 × 15 mL), and the residue was immediately resolved in dry DCM (10 mL). This solution was then added dropwise to a solution of the amino compound (2.4 mmol) in dry DCM (5 mL) and stirred at 25 • C for 2 h. After usual aqueous work-up, the solvent was removed under reduced pressure and the crude products were subjected to column chromatography (silica gel, chloroform/methanol mixtures). Compounds 11-15, 21-25, 31-35 , and 41-45 were each obtained as colorless solids.
General Procedure C for the Deacetylation of Triterpenoic Amides (16-20, 26-30, 36-40, and 46-50)
To a solution of the acetylated amide (0.33 mmol) in methanol (10 mL) was added a solution of potassium hydroxide (1.65 mmol) in methanol (2 mL). The mixture was stirred at 25 • C for 2 or 3 days. After completion of the reaction (as indicated by TLC), aq. HCl was added until pH = 7. After usual work-up, the solvent was removed under reduced pressure and the residue was subjected to column chromatography (silica gel, chloroform/methanol mixtures) yielding compounds 16-20, 26- 53-4.45 (m, 1H, 3-H), 3.68-3.56 (m, 1H, 31-H a ), 3.40-3.29 (m, 1H, 31-H b ), 3. 2H, 2.65 (dd, J = 12.7, 4.6 Hz, 1H, 22-H b ), 1. 22-1.11 (m, 2H, 19-H b , 21-H 46.6 (C-19), 46.3 (C-17) , 41.8 (C-14) , 41.4 (C-18), 40.4 (C-32), 39.4 (C-8) , 38.2 (C-1), 38.1 (C-31), 37.7 (C-4), 36.9 (C-10), 34.2 (C-21), 33.1 (C-30), 32.3 (C-22) , 32.2 (C-7), 30.6 (C-20), 28.0 (C-23), 27.2 (C-15) , 25.8 (C-27), 23.6 (C-2) , 21.3 (Ac), , 16.9 (C-26) , 16.7 (C-24) , 15.5 (C-25) 5.37 (t, J = 3.6 Hz, 1H, 5.08 (ddd, J = 11.1, 10.9, 4.6 Hz, 1H, 4.73 (d, J = 10.3 Hz, 1H, 1H, 1H, ), 2.87-2.76 (m, 2H, 32-H), 2.56 (dd, J = 13.1, 4.3 Hz, 1H, 18-H), 2.04 (s, 3H, Ac), 2.08-1.83 (m, 4H, 1-H a , 16-H a , 11-H a , 11-H b ), 1.97 (s, 3H, Ac), 1.80-1.24 (m, 11H, 19-H a, 22-H a , 16-H b , 9-H, 22-H ν = 3374w, 2941m, 1622m, 1530m, 1456m, 1387s, 1361s,  1344s, 1322s, 1187m, 1137m, 1097m, 1023m , 996m, 825m cm −1 ; 1 H-NMR (500 MHz, CD 3 OD): δ = 5.36 (t, J = 3.7 Hz, 1H, 12-H), 3.50-3.43 (m, 1H, 31-H a 5.36 (t, J = 3.7 Hz, 1H, 3.61 (ddd, J = 11.3, 9.5, 4.5 Hz, 1H, 1H, 1H, 2.90 (d, J = 9.6 Hz, 1H, 2.89 (t, J = 6.5 Hz, 2H, 2.81 (dd, J = 13.5, 4.5 Hz, 1H, 1H, 3H, ), 1.78 (t, J = 13.5 Hz, 1H, ), 1.70-1.26 (m, 10H, 9-H, 22-H a , 15-H a , 16-H b , 6-H a , 22-H b , 7-H a , 6-H b , 21-H a , 7-H b ), 1. 23-1.13 (m, 2H, 19-H b , 21-H b ), 1.18 (s, 3H, 27-H), 1.10-1.02 (m, 1H, 15-H b ), 1.01 (s, 3H, 23-H), 1.00 (s, 3H, 25-H), 0.95 (s, 3H, 30-H), 0.91 (s, 3H, 29-H), 0.93-0.89 (m, 1H, 1-H b ) , 0. 88-0.82 (m, 1H, 5-H), 0.80 (s, 3H, 24-H), 0.78 (s, 3H, 26-H) ppm; 13 C-NMR (101 MHz, CD 3 OD): δ = 181. 5 (C-28), 145.2 (C-13), 123.9 (C-12), 84.4 (C-3), 69.4 (C-2), 56.6 (C-5), 48.9 (C-9) , 48.1 (C-1), 47.6 (C-17), 47.5 (C-19), 42.9 (C-14) , 42.5 (C-18), 41.2 (C-32), 40.7 (C-8), 40.5 (C-4), 40.4 (C-31), 39.2 (C-10), 35.1 (C-21), 34.3 (C-22), 33.7 (C-7), 33.5 (C-30), 31.6 (C-20), 29.3 (C-23), 28.5 (C-15) , 26.5 (C-27), 24.6 (C-11), 24.0 (C-29), 23.9 (C-16), 19.5 (C-6), 17.9 (C-26), 17.4 (C-24), 17.1 (C-25) H 10.57, N 5.44; found: C 74.49, H 10.74, N 5.28 . 3-acetyloxy-olean-12-en-28-amide (22) , Compound 22 was prepared from 7 according to general procedure B using N,N-dimethylethylene diamine as amino compound. Column chromatography (SiO 2 , CHCl 3 /MeOH 95:5) gave 22 (yield: 95%); m.p. [227] [228] [229] [230] • C (decomp.), Lit.: 255 • C (decomp.) [29] ; [α] 6.77 (t, J = 5.3 Hz, 1H, NH), 5.38 (t, J = 3.6 Hz, 1H, 1H, 1H, 1H, 2H, 1H, 2.61 (s, 6H, 2.03 (s, 3H, Ac), 1H, ), 1.93-1.85 (m, 2H, 11-H a , 11-H b ), 1.72 (t, J = 13.4 Hz, 1H, ), 1.66-1.22 (m, 13H, 22-H a 16-H b , 9-H, 22-H b , 6-H a , 15-H a , 7-H a , 6-H b , 21-H a , 7-H b ), 1. 21-1.14 (m, 2H, 19-H b , 21-H b ), 1.14 (s, 3H, 27-H), 1.10-0.97 (m, 2H, 1-H b , 15-H b ) , 0.92 (s, 3H, 25-H), 0.90 (s, 3H, 29-H), 0.89 (s, 3H, 30-H), 0.85 (s, 3H, 23-H), 0.84 (s, 3H, 24-H), 0.83-0.79 (m, 1H, 5-H), 0.74 (s, 3H, 26-H) -13), 123.1 (C-12), 81.0 (C-3), 57.8 (C-32), 55.4 (C-5), 47.6 (C-9), 46.6 (C-19) , 46.5 (C-17), 44.7 (C-33, C-33 ), 42.0 (C-14) , 41.9 (C-18), 39.6 (C-8), 38.3 (C-1), 37.8 (C-4), 37.0 (C-10), 36.1 (C-31), 34.3 (C-21), 33.2 (C-30), 32.9 (C-22), 32.5 (C-7), 30.8 (C-20), 28.2 (C-23) , 27.5 (C-15) , 25.9 (C-27) , 23.7 (C-29) , 21.4 (Ac), , 16.8 (C-26) , 15.6 (C-25) H 10.63, N 4.92; found: C 75.86, H 10.83, N 4.77 . 3-diacetyloxy-olean-12-en-28-amide (23) 15-H b 5.40 (t, J = 3.6 Hz, 1H, (m, 1H, 31-H a ), 1H, 3.21 (dd, J = 11.4, 4.3 Hz, 1H, 2H, 1H, 2.60 (s, 6H, 1.99 (ddd, J = 13.7, 13.6, 3.9 Hz, 1H, ), 1.93-1.89 (m, 2H, 11-H a , 11-H b ), 1.73 (t, J = 13.4 Hz, 1H, ), 1.68-1.30 (m, 12H, 22-H a , 16-H b 9-H, 22-H b , 6-H a , 15-H a , 7-H a , 6-H b , 21-H a ), 1.26 (ddd, J = 12.3, 3.0, 2.9 Hz, 1H, ), 1. 22-1.14 (m, 2H, 21-H b , 19-H b ), 1.15 (s, 3H, 1.05 (ddd, J = 14.1, 3.6, 3.5 Hz, 1H, 25.9 (C-27), 23.7 (C-16), 23.7 (C-29) , 23.6 (C-11), 18.5 (C-6), 17.2 (C-26), 15.7 (C-24) , 15.5 (C-25) H 11.10, N 5.32; found: C 77.37, H 11.31, N 5.16 . , 2946s, 2862s, 2826m, 2778m, 1636s, 1522m, 1462s, 1386m, 1364m, 1266w, 1188w, 1158w, 1098w , 1050s cm −1 ; 1 H-NMR (400 MHz, CDCl 3 ): δ = 6.56 (t, J = 4.9 Hz, 1H, NH), 5.35 (t, J = 3.6 Hz, 1H, 3.68 (ddd, J = 11.3, 9.5, 4.5 Hz, 1H, 1H, 
Conclusions
In this study, 40 triterpenoic acid amides , with different triterpenoic backbones and various amine residues were synthesized and subjected to Ellman's assay to determine their potential as inhibitors of cholinesterases. Furthermore, some enzyme kinetic studies were performed. Thus, systematic variation of the amine substituent led to analogs possessing the same or even better BChE-inhibiting properties as standard galantamine hydrobromide. Outstanding derivatives were 2-pyrrolidin-1-ylethyl substituted compounds 34 (from BA), 36 (from UA), and 37 (from OA), showing K i values of 0.39 ± 0.04 µM, 0.47 ± 0.08 µM, and 0.55 ± 0.02 µM, respectively. Furthermore, Ellman's assay revealed several platanic acid compounds as excellent inhibitors of BChE. Particularly, 40, 45, and 50 were great inhibitors, showing inhibition rates even in the nanomolar range. The most active compound in the test was a hybrid holding a platanic acid backbone and a pyrrolidinyl residue. For (3β)-N-(2-pyrrolidin-1-ylethyl)- 3-acetyloxy-20-oxo-30-norlupan-28-amide (35) , inhibition constants K i = 0.07 ± 0.01 µM and K i = 2.38 ± 0.48 µM have been determined. The results obtained in the biological assay can be explained by appropriate molecular modeling calculations. All active compounds were mixed-type BChE inhibitors with a dominating competitive part (K i < K i ). The best inhibitor for acetylcholinesterase was a betulinic acid derived piperidinyl derivative (49), acting as a mixed-type inhibitor showing K i = 1.00 ± 0.09 µM and K i = 1.42 ± 0.08 µM, respectively.
